Reportlinker.com

Reportlinker.com

March 26, 2008 16:54 ET

High Growth Reported for the World Drug-Eluting Stents Market

LONDON, UNITED KINGDOM--(Marketwire - March 26, 2008) - Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.

World Drug-Eluting Stents Market

This report analyzes the worldwide markets for Drug-Eluting Stents in Millions of US$. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2003 through 2015. The report profiles 39 companies including many key and niche players worldwide such as Abbott Vascular, Angiotech Pharmaceuticals, Inc., AngioDynamics(R), Inc., Boston Scientific, Inc., Boston Scientific Cardiac Rhythm Management, Biocompatibles International PLC, Biosensors International Pte Ltd., Cordis Corporation, Implant Sciences Corporation, Medtronic, Inc., MIV Therapeutics, Inc., and SurModics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level: I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. Market Overview II-1

Current and Future Analysis II-1

Regional Analysis II-1

Major Issues and Trends II-2

Drug-Eluting Stents Transforming the Scenario of

Interventional Cardiology Market II-2

Table 1: World DES Market (2001, 2003 and 2005): Sales Comparison of CABG, Bare-Metal Stents and Drug-Eluting Stents (In '000 units) (includes corresponding Graph/Chart) II-2

Adverse Effects Restrict Market Growth II-3

Innovation and Development Drive Market Growth II-3

High Price of DES- A Major Impediment to Rapid Development II-3

Potential Decline in Hospital Revenues II-3

Glaring Lack of Health-Related Initiatives World Over II-4

Bioabsorbable Stents Closer to Reality Than Expected II-4

2. Coronary Stenting - An Insight II-5

Cardiovascular Diseases -A Brief Description II-5

Table 2: World Market for Cardiovascular Therapies (2006): Percentage Share Breakdown of Value Sales by Product Category-Drug-Eluting Stents, Cardiac Resynchronization Therapy, Cardiac Markers, Portable Automated External Defibrillators, and Angiogenesis/Gene Therapy ($ Millions) (includes corresponding Graph/Chart) II-5

Coronary Heart Disease II-6

Traditional Methods of Treating Blockage of Coronary Arteries II-6

Percutaneous Transluminal Coronary Angioplasty (PTCA) II-6

Coronary Artery Bypass Graft (CABG) II-6

Restenosis II-6

Evolution of Coronary Stents as a Replacement for Traditional Methods II-6

What are Coronary Stents? II-7

How is Coronary Stenting Performed - Procedure II-7

Risks and Problems Associated with Placing a Stent II-7

Restenosis Still Pervasive Even after the Use of Stents II-7

Market Analysis for Coronary Stents II-7

By Types II-7

Table 3: World Coronary Stents Market (2005 & 2006 E): Percentage Share Breakdown of Value Sales by Type- Eluting and Bare II-7

By Region/Country II-8

Table 4: World Market for Coronary Stents (2006): Percentage Share Breakdown of Value Sales by Region/ Country -US, Japan, Europe, Japan, and Rest of World (includes corresponding Graph/Chart) II-8

By Major Players II-8

Table 5: World Market for Coronary Stents (All Stents) (2005- 2007): Percentage Share Breakdown of Value Sales by Major Players- Johnson & Johnson, Guidant, Boston Scientific, Medtronic, Abbott, and Others (includes corresponding Graph/Chart) II-8

In-Stent Restenosis - Outcome of Bare Metal Stents II-9

In-Stent Restenosis - Definition II-9

Causes of In-Stent Restenosis II-9

3. Product Overview II-10

A Brief Introduction to DES II-10

Suitable Patient Types for Drug-Eluting Stents II-10

Major Drugs Used in DES II-10

Sirolimus II-10

Paclitaxel II-10

Other Treatments Available for Treating In-Stent Restenosis II-11

Major Drug-Eluting Stent Products in the Market II-11

World Market for Drug-Eluting Stents (2002 - 2007): DES Brands Launched by Major Manufacturers- Cordis, Boston Scientific, Cook Group, Guidant, and SMT II-11

Table 6: World Drug Eluting Stents Market (2006 ): Percentage Share Breakdown of Sales by Leading DES Brands - Cypher, Taxus, and Others (includes corresponding Graph/Chart) II-12

Cypher II-12

Taxus II-12

4. Competitive Scenario II-14

Drug-Eluting Stents-Competitive Arena II-14

Table 7: World Drug Eluting Stents Market (2005-2008): Percentage Breakdown of Value Sales by Leading Players - Johnson & Johnson, Boston Scientific, Medtronic, Abbott, Conor, and Others (includes corresponding Graph/Chart) II-14

Market Dominated by Small Band of Players II-15

Cordis (A Johnson & Johnson Company) II-15

Cypher Leads the Drug-Eluting Stent Market II-15

Boston Scientific II-15

Taxus Beats Cypher in the US II-15

5. Cost and Price Economics II-16

Cost Evaluation of DES II-16

Initial Procedural Costs Remain High II-16

Table 8: Average Price Per DES Unit for the Period 2004-2005 II-16

Table 9: Worldwide Average Stent Prices (2002-2005): Breakdown of Regions by Drug Eluting Stents and Bare Metal Stents (includes corresponding Graph/Chart) II-17

Follow-Up Costs Provide Relief II-17

Table 10: A Comparative Presentation of Long-Term Costs of DES and CABG II-17

Conversion of CABG Procedures to DES II-17

Impact of DES on Indirect Costs II-18

6. Research and Development Initiatives II-19

Boston Completes European and Intercontinental Enrollment Phases II-19

Medtronic To Start Clinical Study II-19

Guidant Accomplishes Patient Enrollment II-19

Abbott Receives FDA Approval for Initiation of ZoMaxx Clinical Trials II-19

Medtronic Commences Endeavor I Clinical Trial II-20

MIV Therapeutics Completes Drug-Eluting Stent Coating R&D Program II-20

Guidant Conducts First Implant as Part of Drug Eluting Stent Trial II-20

Medtronic's Endeavor Drug Eluting Stent Shows Positive Results II-20

Cypher(TM) Coronary Stent Trial Show Restenosis Rates Decline by 5.1% II-20

Boston Scientific Demonstrates Positive Results for Taxus IV Clinical Trial II-21

Medtronic Initiates Endeavor Clinical Trials for Endeavor Drug Eluting Stent II-21

Guidant's Clinical Trials for Coronary Stent Demonstrates Positive Results II-21

Clinical Trials Undertaken from 2002-2007 II-21

MIV Commences Clinical Trials of HC Stent II-21

XTNT Voiced CUSTOM I Trial Program of NX(TM) DES System II-22

Dynatek Completes DES Coating Durability Trial II-22

STEALTH Trial II-22

SIROCCO Trial II-22

Cook Trial II-23

ZoMAXX Trial II-23

Ravel Trial II-23

Sirius Trial II-23

C - Sirius Trial II-23

E - Sirius Trial II-23

Taxus I through VI Clinical Trials II-23

Other Clinical Trials II-24

7. Regulatory Environment II-25

FDA Framework II-25

FDA to Monitor Drug-Eluting Stents II-25

Issues Raised by FDA Regarding the Safety of Stent II-25

Major DES Products Approved by FDA II-25

FDA Approves Boston Scientifis's Taxus Stent with Extended Shelf Life II-25

Conor COSTAR Receives US FDA Approval II-25

Boston Scientific's Taxus Gets FDA Approval II-26

Cypher Stent Receives Approval from FDA II-26

Concerns Raised by FDA II-26

8. Recent Industry Activity II-27

MIV Therapeutics Acquires Biosync Scientific II-27

J & J Acquires Conor Medsystems II-27

Lombard Collaborates With S&N II-27

India Establishes Asia's first Catheter and Stent Unit. II-27

Abbott Requests FDA Approval for Xience II-27

Brookwood and TTV Start Joint Venture II-27

SurModics Acquires Brookwood Pharmaceuticals, Inc II-28

ARIAD Collaborates with ICON Medical II-28

Biosensors Acquires 50% Stake in JWMS II-28

Cordis' Cypher Select(TM) Plus Receives Approval in Europe II-29

Boston Scientific Acquires Guidant for $27 Billion, Abbott Gets Guidant's Vascular and Cardiac Therapies Businesses as Part of Deal II-29

Abbott Expands Vascular Sites in Ireland II-29

Medtronic's Endeavor(R) Attains Reimbursement Approval in France II-29

SurModics Offers License for Hydrophilic Technology to Devax II-29

Conor obtains License for Novartis' Pimecrolimus II-29

Medtronics Makes Final PMA Submission for Endeavor II-30

Volcano Collaborates with CRF, Cardialysis and Stanford University II-30

Boston's PROMUS Receives CE Mark Approval II-30

SurModics and X-Cell Inks Licensing Agreement II-30

Medtronic Receives Regulatory Approval for Endeavor (R) II-31

Medtronics' Endeavor Obtains Chinese Regulatory Approval II-31

Biosensors Collaborates with JW Medical II-31

Biosensors and Weigao To Consolidate Joint Venture II-31

Biotronik Enters Multi-Drug Deal with Novartis II-31

MIVT Enters Collaboration Deal with SMT II-32

SMT's Infinnium Paclitaxel System Receives CE Mark II-32

Guidant's Xience V Receives European Approval II-32

Medtronic Files Initial PMA Module TO US FDA II-32

Boston Scientific Receives European Approval for TAXUS(R) II-32

Biosensors Attains US Patent Covering DES Technology II-33

MediVas LLC and Estracure Inc Sign Agreement for Development of DES II-33

Relisys Medical of India Finalizes Deal with Germany Based Blue Membranes II-33

X-cell Medical Enrolls for Clinical Trial of ETHOS I Estradiol Eluting Stent. II-33

Biosensors International Group Receives CE Approval for First DES, Axxion II-33

Boston Scientific Corp Receives CE Mark Approval for Marketing Larger Stent Sizes II-34

Medtronic Receives CE Mark Approval for Commercial Sale of Endeavor DES in Europe II-34

Biosensors International Opens New Interventional Cardiology Unit in Singapore II-34

Johnson & Johnson Recalls Cypher Drug-Eluting Stents II-34

Boston Scientific Buys Out Precision Vascular Systems II-34

Implant Sciences and CardioTech International enter into Partnership with CorNova II-35

Avantec Vascular Corporation Signs Agreement with Novartis Pharma AG II-35

Guidant and Cordis Enter into Promotion Agreement II-35

Genvec Collaborates with Cordis II-35

Cordis Receives Approval from Japanese Ministry of Health II-35

Boston Scientific Modifies Production of Taxus Drug-Eluting Stent II-36

Guidant Acquired CE Mark Approval for Multi-Link Bifurcation Stent System II-36

Boston Scientific Receives Reimbursement Approval from French Government II-36

Boston Scientific Withdraws Consortium of Drug-Coated Stents II-36

AVD Acquires the Assets of Jomed's Coronary and Peripheral Business Line II-36

Guidant Acquires Biosensors' Everolimus Eluting Stent Assets II-37

Biosensors Signs Distribution Agreement with Terumo II-37

Guidant Obtains the Rights of Polymer Technologies Developed By MediVas II-37

Biosensors Pens a Deal with X-Cell to Start Drug-Eluting Stent Company II-37

Debiotech Receives Global License to Drug Eluting Stent Technology II-38

Boston Scientific Markets Drug-Eluting Stents to Indian Market II-38

Hoag Heart First to Receive New Drug-Eluting Stents II-38

Abbott Purchases Biocompatibles' Cardiovascular Stent Business II-38

Guidant Takes Over Cook Group II-38

Medtronic Enters into a Co-Exclusive Agreement with Abbott II-38

Angiotech Accords with NeoRx for Paclitaxel License II-39

Novartis Pharma AG Enters into a Licensing Agreement with Guidant II-39

Cordis Declares Positive Results in Bifurcation Feasibility Study II-39

PharmaSonics Initiates the Clinical Trials for Intravascular Sonotherapy II-39

Guidant Declares Deliver Clinical Trial Results II-39

Clinsights Opens a Drug-Eluting Stent Center II-40

Boston Scientific Acquires Global Co-Exclusive Rights from Angiotech II-40

Angiotech Pharmaceuticals Elucidates the Conclusions of Taxus I Clinical Trial II-40

Boston Scientific Proclaims Zero Restenosis for Taxus Drug- Eluting Stent Trial II-40

Boston Scientific Conducts Taxus I ISR Clinical Trial II-40

9. Product Innovations/Introductions II-41

Abbott Launches Drug-Eluting Coronary Stent II-41

Boston Introduces Taxus(R) Express2(TM) in Japan II-41

Cordis Brings Advanced Drug-Eluting Stent II-41

Sorin Unveils Enhanced Janus Flex in Europe II-41

EUREKA Develops Latest Generation of Drug- Eluting Stent II-42

MIV Therapeutics Develops New Drug Eluting Coating Technology in Canada II-42

Medtronic to Launch Endeavor DES in Europe II-42

DISA Vascular (Pty) Ltd Introduces ChromoFlex in Europe II-43

Boston Scientific Introduces Taxus Liberte Drug Eluting Stent in Europe II-43

Boston Scientific Introduces Innovative Drug-Eluting Stent, Taxus in the US Market II-43

Johnson & Johnson Introduces Drug-Eluting Stent II-43

MIV Therapeutics to Introduce Advanced Biocompatible Coatings II-44

Guidant Develops Champion Drug-Eluting Stent System II-44

University of Virginia Launches Drug-Eluting Stent II-44

Implant Sciences and CardioTech Jointly Develop Drug Eluting Stent II-44

Boston Scientific Introduces Express(TM) Stent in the European Market II-45

10. Focus on Select Global Players II-46

Abbott Vascular (USA) II-46

Angiotech Pharmaceuticals, Inc (Canada) II-46

AngioDynamics(R) Inc. (USA) II-46

Boston Scientific, Inc. (USA) II-47

Boston Scientific Cardiac Rhythm Management (USA) II-47

Biocompatibles International Plc (UK) II-47

Biosensors International Pte Ltd. (Singapore) II-48

Cordis Corporation (USA) II-48

Implant Sciences Corporation (USA) II-48

Medtronic, Inc.(USA) II-48

MIV Therapeutics Inc (Canada) II-49

SurModics, Inc. (USA) II-49

11. Global Market Perspective II-51

Table 11: World Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region - US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) II-51

Table 12: World Long-term Projections for Drug-Eluting Stents by Geographic Region - US, Japan, Europe and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-51

Table 13: World 7-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of the World Markets for Years 2003, 2007, & 2010 (includes corresponding Graph/Chart) II-52

III. MARKET

1. The United States III-1

A.Market Analysis III-1

Current and Future Analysis III-1

Issues and Trends III-1

US Healthcare Ideology III-1

The Important Role of Medicaid in the US III-2

Drug-Eluting Stents-Competitive Arena III-2

Table 14: US Market for Coronary Stents (2005 - 2007): Percentage Share Breakdown of Value Sales by Leading Players- Abbott/Guidant, Medtronic, Johnson & Johnson, and Boston Scientific (includes corresponding Graph/Chart) III-2

Table 15: US Market for Drug Eluting Stents (2005 - 2008): Percentage Share Breakdown of Sales Revenue by Major Players- Johnson & Johnson, Boston Scientific, Medtronic, Abbott, and Conor (includes corresponding Graph/Chart) III-3

US Market for Drug-Eluting Stents (2003 - 2007): DES Products Launched by Major Manufacturers - Cordis (Johnson & Johnson), Boston Scientific, and Cook Group III-3

Leading DES Products in the Market III-3

Cypher - First to Market III-3

Taxus Beats Cypher III-4

Regulatory Environment III-4

FDA Framework III-4

Issues Raised by FDA Regarding the Safety of Stent III-4

Major Drug-Eluting Stents Approved by FDA III-4

FDA Approvals in the Recent Past III-5

Key Players III-5

Product Innovations/ Introductions III-8

Product Innovations/Introductions in the Recent Past III-9

Recent Industry Activity III-10

B.Market Analytics III-20

Table 16: US Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-20

Table 17: US Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-20

2. Japan III-21

A.Market Analysis III-21

Current and Future Analysis III-21

Healthcare System in Japan III-21

Table 18: Japanese Market for Drug Eluting Stents (2005-2008): Percentage Share Breakdown of Sales Revenue by Major Players- Johnson & Johnson Boston Scientific, and Medtronic (includes corresponding Graph/Chart) III-21

Table 19: Japanese Market for Stents (2005-2007): Percentage Share Breakdown of Sales Revenues by Major Players- Abbott/Guidant, Medtronic, Johnson & Johnson, Boston Scientific, and Others (includes corresponding Graph/Chart) III-22

Key Player III-22

Product Innovations/ Introductions III-22

Industry Activity in the Recent Past III-23

B.Market Analytics III-23

Table 20: Japanese Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-23

Table 21: Japanese Long-term Projections for Drug- Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-24

3. Europe III-25

A.Market Analysis III-25

Healthcare System in Europe III-25

Current and Future Analysis III-25

Regional Analysis III-25

Issues and Trends III-25

Reimbursement a Major Hurdle in European Market Penetration of DES III-25

Slow Market Penetration of New Medical Devices in Europe III-26

Taxus - Leading the European Stent Market III-26

Leading DES Players in the Market III-26

Table 22: European Market for Drug Eluting Stents (2005-2008): Percentage Share Breakdown of Sales Revenue by Major Players- Johnson &Johnson, Boston Scientific, Medtronic, Abbott, Conor, and Others (includes corresponding Graph/Chart) III-26

Table 23: European Market for Stents (2005-2007): Percentage Share Breakdown of Sales Revenue by Major Players- Abbott/Guidant, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) III-27

Key Players III-27

Product Innovations/Introductions III-28

Recent Industry Activity III-30

Industry Activity in the Recent Past III-32

B.Market Analytics III-33

Table 24: European Recent Past, Current and Future Analysis for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) (includes corresponding Graph/Chart) III-33

Table 25: European Long-term Projections for Drug-Eluting Stents by Geographic Region - France, Germany, Italy, UK, Spain and Rest of the Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-34

Table 26: European 7-Year Perspective for Drug-Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2003, 2007 and 2010 (includes corresponding Graph/Chart) III-34

3a. France III-35

A.Market Analysis III-35

Healthcare System in France III-35

Current and Future Analysis III-35

Recent Industry Activity III-35

B.Market Analytics III-36

Table 27: French Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-36

Table 28: French Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-36

3b. Germany III-37

A.Market Analysis III-37

Health Care Policies in Germany III-37

Lower Market Penetration of DES III-37

B.Market Analytics III-38

Table 29: German Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-38

Table 30: German Long-term Projections for Drug- Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-38

3c. Italy III-39

A.Market Analysis III-39

Current and Future Analysis III-39

Italian Healthcare System III-39

Local Healthcare Agencies III-39

National Health System in Italy III-39

B.Market Analytics III-40

Table 31: Italian Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-40

Table 32: Italian Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-40

3d. The United Kingdom III-41

A.Market Analysis III-41

Current and Future Analysis III-41

National Health System in the UK III-41

Key Player III-41

Recent Industry Activity III-41

B.Market Analytics III-42

Table 33: UK Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-42

Table 34: UK Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-42

3e. Spain III-43

A.Market Analysis III-43

Current and Future Analysis III-43

Healthcare System in Spain III-43

B.Market Analytics III-43

Table 35: Spanish Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-43

Table 36: Spanish Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-44

3f. Rest of Europe III-45

A.Market Analysis III-45

Crumbling Healthcare System in Rest of Europe III-45

Current and Future Analysis III-45

Recent Industry Activity III-45

B.Market Analytics III-46

Table 37: Rest of Europe Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-46

Table 38: Rest of Europe Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-46

4. Rest of World III-47

A.Market Analysis III-47

Current and Future Analysis III-47

Asia-Pacific III-47

Key Player III-47

Recent Industry Activity III-47

Canada III-49

Key Players III-49

Product Innovations/Introductions III-50

Recent Industry Activity III-50

B.Market Analytics III-52

Table 39: Rest of the World Recent Past, Current and Future Analysis for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2010 (includes corresponding Graph/Chart) III-52

Table 40: Rest of World Long-term Projections for Drug-Eluting Stents Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-53

IV. COMPETITIVE LANDSCAPE

To order this report:

World Drug-Eluting Stents Market

More market research reports here!

Contact Information